Latest news for Fantex (OTC:BRKSL) Stock

Fantex Inc is a marketing services provider in the United States. Its range of operations covers brand acquisition, marketing and brand development in the interest of professional athletes, entertainers, and other high-profile individuals. Fantex's strategy revolves around 3 pillars; Evaluation, Acquisition, and Enhancement. Evaluation is the analysis done before the company enters a brand agreement. Acquisition relates to the initial steps of acquiring a brand such as negotiation of brand price etc and Enhancing Brand Value is where the company builds a portfolio of brands and enhances them with the help of technology and data applications.

Fantex Inc

Novo Integrated Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares are blasting higher Thursday after-hours after the company announced it received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (SBLC) <a href="https://www.benzinga.com/pressreleases/24/07/b39848094/novo-integrated-sciences-receives-commencement-of-disbursement-notice-for-sblc-leasing-and-monetiz">and monetization program.</a>
The Details: As previously reported, Novo entered into an application whereby the company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetization program.
Novo said the initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the company. With this initial disbursement, the Novo expects final distribution to follow on or before August 2. 
Read Next:<a href="https://www.benzinga.com/news/earnings/24/07/39826835/discover-reports-better-than-expected-q2-results-heres-the-details"> Discover Reports Better-Than-Expected Q2 Results: Here&#8217;s The Details</a>
&#8220;The commencement of distribution marks the first payments in the process of full monetization of the SBLC. This step will now lead us to receiving our full expected payout as identified in the transaction documents. We look forward to engaging in our intended initiatives,&#8221; said Robert Mattacchione, Novo&#8217;s CEO.
NVOS Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Novo Integrated Sciences shares are up 34.73% after-hours at 81 cents at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39827454/what-happened-with-intel-stock-today">What Happened With Intel Stock Today?</a></li>
</ul>
Image: Pete Linforth from Pixabay

News

Penny Stocks

After-Hours Center

Movers

NVOS

Why Novo Integrated Sciences Stock Is Up

Macquarie analyst Paul Golding initiates coverage on Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Outperform rating and announces Price Target of $64.

Price Target

Initiation

Analyst Ratings

Macquarie Initiates Coverage On Six Flags Entertainment with Outperform Rating, Announces Price Target of $64

The offering of the Notes is expected to close on&nbsp;July 25, 2024, subject to customary closing conditions.&nbsp;SM Energy intends to use the net proceeds from the offering of the Notes, together with cash on hand and borrowings under its Credit Agreement, to fund the purchase price for SM Energy&#39;s recently announced pending acquisition of certain oil and gas properties, interests, and related assets located in the Uinta Basin from certain entities affiliated with XCL Resources, LLC, to redeem all of its outstanding&nbsp;5.625%&nbsp;Notes due 2025, and to pay related fees and expenses.&nbsp;

Offerings

SM Energy Prices Upsized Offering Of $750M Of Its 6.750% Senior Notes Due 2029 And $750M Of Its 7.000% Senior Notes Due 2032

Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) with a Buy, adjusts target to $40 from $4 ((reverse stock split 1:10)).

ADVM

Chardan Capital Maintains Buy on Adverum Biotechnologies, Adjusts Price Target To $40 ((reverse stock split 1:10))

Hawaiian Electric Soars On Report Of Maui Fire Settlement Plan; Agreement Would Resolve Claims From Deadly Lahaina Fire; Size Of Potential Settlement Has Not Been Publicly Disclosed

Earnings

Earnings Beats

Earnings Misses

MBCN

Middlefield Banc Q2 2024 Sales $16.843M Miss $16.867M Estimate

Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.16) by 106.25 percent. This is a 105.88 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $14.001 million which beat the analyst consensus estimate of $12.692 million by 10.31 percent. This is a 7.11 percent increase over sales of $13.071 million the same period last year.

CSBR

Champions Oncology Q4 2024 Adj EPS $0.01 Beats $(0.16) Estimate, Sales $14.001M Beat $12.692M Estimate

Middlefield Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBCN#NASDAQ">MBCN</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.40 by 30 percent. This is a 17.46 percent decrease over earnings of $0.63 per share from the same period last year.

Middlefield Banc Q2 2024 GAAP EPS $0.52 Beats $0.40 Estimate

Guidance

NFLX

Netflix CFO Says Ads Will Become A "Meaningful Contributor" To Revenue By 2026

Corsair Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>) shares are trading lower in Thursday&#8217;s after-hours session after the company reported <a href="https://www.benzinga.com/pressreleases/24/07/b39847898/corsair-gaming-to-report-q2-2024-financial-results-on-august-1-provides-preliminary-q2-2024-result">preliminary results for the second quarter</a>.
What Happened: After the market close on Thursday, Corsair announced that it expects to report second-quarter revenue of approximately $261 million versus estimates of $319.977 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
&#8220;The market for high-end self-built gaming PCs continues to be softer than expected as we are seeing consumers waiting for new GPUs to be launched at year-end. This has been somewhat offset by good activity in the entry-level market where gamers are using lower-cost GPUs and CPUs, but the net effect of this has been to lower market ASPs for some of the component categories we sell,&#8221; said Andy Paul, CEO of Corsair.
&#8220;Channel inventory has generally been reduced for our products, and so during&nbsp;Q2&nbsp;we sold into the channel substantially less than was sold out to consumers. Overall in the Gaming Components and Systems segment, this resulted in disappointing results for revenue and margins, but we do expect this to recover in the second half of 2024 and 2025.&#8221;
Corsair scheduled its <a href="https://www.benzinga.com/calendars/earnings">second-quarter results</a> for Aug. 1. The company said it will hold a conference call to discuss its quarterly performance at 5 p.m. ET that day.
CRSR Price Action: Corsair Gaming shares were down 7.41% at $9 in after-hours trading after falling more than 5% in the regular session, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39849026/netflix-q2-earnings-highlights-revenue-beat-eps-beat-advertising-revenue-more-meaningful-squid-game">Netflix Q2 Earnings Highlights: Revenue Beat, EPS Beat, Advertising Revenue &#8216;More Meaningful,&#8217; &#8216;Squid Game&#8217; Multiplayer Game Coming</a></li>
</ul>
Photo: Timur Kozmenko from Pixabay.

CRSR

Corsair Gaming Stock Slides As Consumers Hold Out For New GPUs: What Investors Need To Know

In the latest quarter, 4 analysts provided ratings for Frontier Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYBR#NASDAQ">FYBR</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $33.25, a high estimate of $39.00, and a low estimate of $29.00. Highlighting a 6.34% decrease, the current average has fallen from the previous average price target of $35.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1721336460_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Frontier Communications is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batya Levi</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Frontier Communications. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Frontier Communications compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Frontier Communications's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Frontier Communications's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FYBR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Frontier Communications analyst ratings.</a>
<h2>Get to Know Frontier Communications Better</h2>
Frontier Communications Parent Inc offers a variety of services to residential and business customers over its fiber-optic and copper networks, including video, high-speed internet, advanced voice, and Frontier Secure digital protection solutions. It offers communications solutions to small, medium, and enterprise businesses.
<h3>Frontier Communications: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Frontier Communications displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 1.97%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.07%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Frontier Communications's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.02%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Frontier Communications's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.0%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.14, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FYBR

A Glimpse Into The Expert Outlook On Frontier Communications Through 4 Analysts

In the preceding three months, 6 analysts have released ratings for MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $121.67, a high estimate of $135.00, and a low estimate of $110.00. This upward trend is evident, with the current average reflecting a 19.67% increase from the previous average price target of $101.67.
<img src="https://www.benzinga.com/files/images/story/2024/1721336450_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of MACOM Technology Solns's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Richard Shannon</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MACOM Technology Solns. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MACOM Technology Solns compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of MACOM Technology Solns's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into MACOM Technology Solns's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MTSI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MACOM Technology Solns analyst ratings.</a>
<h2>All You Need to Know About MACOM Technology Solns</h2>
MACOM Technology Solutions Holdings Inc is a provider of analog, digital and mixed-signal semiconductor solutions to original equipment manufacturers and distributors. These solutions are found in systems for industrial, medical, scientific, and test and measurement markets. The firm's portfolio of products includes integrated circuits, multichip modules, power pallets and transistors, diodes, amplifiers, switches and switch limiters, passive and active components, and complete subsystems. Roughly a third of the firm's revenue is generated in the United States, with the rest coming from China, Taiwan, and other countries across the world.
<h3>Breaking Down MACOM Technology Solns's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: MACOM Technology Solns displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 6.98%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: MACOM Technology Solns's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 8.27%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.45%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): MACOM Technology Solns's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.9%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: MACOM Technology Solns's debt-to-equity ratio surpasses industry norms, standing at 0.46. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MTSI

Peeling Back The Layers: Exploring MACOM Technology Solns Through Analyst Insights

Analysts' ratings for Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $59.4, with a high estimate of $75.00 and a low estimate of $46.00. Witnessing a positive shift, the current average has risen by 0.25% from the previous average price target of $59.25.
<img src="https://www.benzinga.com/files/images/story/2024/1721336441_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Vital Energy among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Derrick Whitfield</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vital Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vital Energy compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vital Energy's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Vital Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VTLE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vital Energy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Vital Energy Better</h2>
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
<h3>A Deep Dive into Vital Energy's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Vital Energy displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 45.06%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Vital Energy's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -13.78%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vital Energy's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.38%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Vital Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.23%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Vital Energy's debt-to-equity ratio surpasses industry norms, standing at 0.8. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VTLE

Unveiling 5 Analyst Insights On Vital Energy

Across the recent three months, 8 analysts have shared their insights on Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Fortrea Holdings, revealing an average target of $28.75, a high estimate of $36.00, and a low estimate of $26.00. Highlighting a 21.87% decrease, the current average has fallen from the previous average price target of $36.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1721336431_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Fortrea Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$27.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fortrea Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Fortrea Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Fortrea Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Fortrea Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FTRE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fortrea Holdings analyst ratings.</a>
<h2>Discovering Fortrea Holdings: A Closer Look</h2>
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
<h3>A Deep Dive into Fortrea Holdings's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Fortrea Holdings faced challenges, resulting in a decline of approximately -4.58% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Fortrea Holdings's net margin is impressive, surpassing industry averages. With a net margin of -15.25%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Fortrea Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.06%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Fortrea Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.35%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.06, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTRE

Demystifying Fortrea Holdings: Insights From 8 Analyst Reviews

8 analysts have shared their evaluations of Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Crown Castle, revealing an average target of $112.0, a high estimate of $127.00, and a low estimate of $100.00. Highlighting a 0.51% decrease, the current average has fallen from the previous average price target of $112.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1721336421_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Crown Castle by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ari Klein</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Barden</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Brett Feldman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$104.00</td>
<td>-</td>
</tr>
<tr>
<td>Ric Prentiss</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$126.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$112.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Matthew Niknam</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$109.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Crown Castle. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crown Castle compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Crown Castle's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Crown Castle's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Crown Castle analyst ratings.</a>
<h2>All You Need to Know About Crown Castle</h2>
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with about 75% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
<h3>Unraveling the Financial Story of Crown Castle</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Crown Castle's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -7.45% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Crown Castle's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 18.95%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crown Castle's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 5.0%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.81%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 4.82.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Crown Castle's Future

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 12.43% on an annualized basis producing an average annual return of 20.85%. Currently, Illumina has a market capitalization of $18.45 billion. 
Buying $1000 In ILMN: If an investor had bought $1000 of ILMN stock 20 years ago, it would be worth $46,623.49 today based on a price of $115.79 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721336417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ILMN

$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today

America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.94, with a high estimate of $22.60 and a low estimate of $17.20. Witnessing a positive shift, the current average has risen by 0.2% from the previous average price target of $19.90.
<img src="https://www.benzinga.com/files/images/story/2024/1721336411_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of America Movil's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonardo Olmos</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.60</td>
<td>$23.30</td>
</tr>
<tr>
<td>Andres Coello</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$18.90</td>
<td>$19.00</td>
</tr>
<tr>
<td>Andres Coello</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$19.00</td>
<td>$19.60</td>
</tr>
<tr>
<td>Vitor Tomita</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Andres Coello</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$17.20</td>
<td>$16.60</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to America Movil. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of America Movil compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of America Movil's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of America Movil's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on America Movil analyst ratings.</a>
<h2>Unveiling the Story Behind America Movil</h2>
America Movil is the largest telecom carrier in Latin America, serving about 285 million wireless customers across the region. It also provides fixed-line phone, internet access, and television services in most of the countries it serves. Mexico is the firm's largest market, providing about 35% of service revenue. Movil dominates the Mexican wireless market with more than 60% customer share and also serves about half of fixed-line internet access customers in the country. Brazil, its second most important market, provides about 20% of service revenue. Movil sold its low-margin wireless resale business in the U.S. to Verizon in 2021 and now owns a 1.4% stake in the U.S. telecom giant. The firm also holds a 58% stake in Telekom Austria and a 15% stake in Dutch carrier KPN.
<h3>Breaking Down America Movil's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Challenges: America Movil's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -2.69%. This indicates a decrease in top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.64%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): America Movil's ROE stands out, surpassing industry averages. With an impressive ROE of 3.55%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): America Movil's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.85% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: America Movil's debt-to-equity ratio is below the industry average at 1.71, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 5 Analyst Evaluations For America Movil

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 18.07% on an annualized basis producing an average annual return of 31.07%. Currently, Natera has a market capitalization of $12.47 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $386.36 today based on a price of $101.57 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721336412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTRA

Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years

GLP-1 market leaders Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship <a href="https://www.benzinga.com/topic/pharmaceuticals">products, Zepbound and Wegovy.</a>
Shares of Eli Lilly plummeted by 6.3%, marking their worst daily performance since March 2021. In the last two sessions, they have dropped by over 10%, registering the worst two-day downside since March 2020. Similarly, shares of Dutch pharmaceutical giant Novo Nordisk A/S fell 4%. 
Chart: Eli Lilly&#8217;s Worst Session In Over Three Years
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="618" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18161727/image-31-1024x618.png" alt="" class="wp-image-444279" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18161727/image-31-1024x618.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18161727/image-31-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18161727/image-31-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18161727/image-31-1536x928.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18161727/image-31.png 1752w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Image: <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071824&amp;t=be2bearmibe3na1">Benzinga Pro</a>
<h3 class="wp-block-heading">Weight-Loss Market Sees New Entrants</h3>
&#8220;This week is a prime (early) example of why biotech risk needs to be managed and why a Magnificent 7 approach to biotech doesn't work,&#8221; Maurits Pot, founder and CEO at Tema ETFs, exclusively told Benzinga. 
The two weight-loss giants have seen their duopoly position threatened by the entry of new players. First, Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and then Roche Holding Ltd (OTCPK: RHHBY) announced advancements in the development of obesity-fighting drugs. 
However, Pot shows cautiousness in these early findings. &#8220;The initial Roche data on oral small molecule GLP-1 agonist was encouraging but important to note the patient size was only 25, we expect further details in an upcoming medical meeting,&#8221; Pot stated. 
&#8220;Pfizer has had a number of prior setbacks with the early danuglipron formulation,&#8221; he said. This development suggests that Pfizer will now compete closely with Chugai Pharmaceuticals, the first-mover with its oral nonpeptide GLP-1 agonist, orforglipron, which sets a high bar.
&#8220;Pfizer&#8217;s focus on danuglipron is likely to temper any immediate interest in GLP-1 mergers and acquisitions,&#8221; Pot added.
Pot also foresees further developments from other companies, including AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), indicating that the GLP-1 market could eventually include up to five credible players alongside Novo and Lilly.
<h3 class="wp-block-heading">Diversification Is Crucial In This Industry</h3>
Since the inception of the Tema GLP-1, Obesity and Cardiometabolic ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTS#NYSE">HRTS</a>) fund, Tema has consistently believed that the fast-evolving &#8220;GLP-1 market won&#8217;t be dominated by just two players.&#8221; 
Pot explained that the HRTS portfolio reflects this conviction, maintaining decent exposure to both NOVO and LLY while avoiding overly concentrated positions of 30-40% in these companies.
&#8220;The HRTS portfolio leverages Tema's deep biotech expertise to identify early emerging next-generation GLP-1 players beyond NOVO and LLY,&#8221; the expert said. 
Pot highlighted that Tema has been an early investor in several next-generation GLP-1 players such as Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Terns Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>), Chugai, Zealand Pharma A/S (OTCPK: ZLDFF), and Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>). 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39656549/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo">EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO</a></li>
</ul>

Biotech

Equities

Large Cap

Sector ETFs

Small Cap

Exclusives

ETFs

AMGN

HRTS

OZEM

RHHBY

TERN

Amplify ETF Trust Amplify Weight Loss Drug & Treatment ETF

THNR

VKTX

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

Scholastic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) reported its fourth-quarter financial results Thursday. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/07/n39847950/scholastic-reports-fourth-quarter-and-fiscal-2024-results">figures from the report.&nbsp;</a>
The Details: Scholastic reported quarterly earnings of $1.73 per share which missed the analyst consensus estimate of $2.66 by 34.96% and represents a 23.45% decrease in earnings from the same period last year.
Quarterly sales came in at $474.9 million which missed the analyst consensus estimate of $552.496 million by 14.04% and is a 10.11% decrease year-over-year.
&#8220;Scholastic made significant progress last quarter advancing our 360-degree content creation strategy, as we expand our opportunities as a global children&#8217;s media company,&#8221; said Peter Warwick, CEO of Scholastic.
&#8220;With the addition of the award-winning 9 Story Media Group to our portfolio, announced in March and closed last month, our new Scholastic Entertainment segment has gained industry-leading production, distribution and licensing capabilities, an extensive children&#8217;s content library, and a highly talented team,&#8221; Warwick added.
Read More: <a href="https://www.benzinga.com/news/earnings/24/07/39826835/discover-reports-better-than-expected-q2-results-heres-the-details">Discover Reports Better-Than-Expected Q2 Results: Here&#8217;s The Details</a>
Outlook: Scholastic expects fiscal 2025 revenue growth of 4% to 6% and is targeting Adjusted EBITDA of $140 to $150 million, reflecting the partial-year contribution of 9 Story Media Group, partially offset by continuing spending on key growth initiatives and the impact of ongoing pressure on consumer and school spending. In its fiscal first quarter, the company expects a seasonal loss approximately in line with the prior year.
SCHL Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Scholastic Corporation shares are down 6.97% after-hours at $34.01 at the time of publication Thursday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39827454/what-happened-with-intel-stock-today">What Happened With Intel Stock Today?</a></li>
</ul>
Image: Gerd Altmann from Pixabay

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Fantex

News

Latest news for Fantex (OTC:BRKSL) Stock